The Pharmaceutical Journal
Vol 277 No 7408 p39
8 July 2006

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Pfizer to sell OTC business to J&J

Pfizer has reached an agreement to sell its consumer health care business to Johnson & Johnson. The purchase will result in an after-tax revenue of about $13.5bn for Pfizer, which the company is expected to invest in research and development and the acquisition of new products and technologies.